Atlassian Corporation PLC vs State Street SPDR S&P Biotech ETF — how do they compare? Atlassian Corporation PLC trades at $154.17 (market cap $39.10B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Atlassian Corporation PLC nearer its low. Which is the better fit depends on your goals.
| TEAM | XBI | |
|---|---|---|
Market Cap | $39.10B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $182.36 | $164.28 |
52-Week Low | $57.15 | $86.92 |
Enterprise Value | $39.09B | — |
Signals from Pluang's Aura AI — not financial advice
Atlassian (TEAM) trades at $155.15, up 2.16% with strong momentum following a 35% surge post-earnings. The stock shows bullish technical signals with moving averages supporting upward trends, though RSI indicates overbought conditions. Fundamentally, revenue growth remains robust at 28% YoY in Q4 2026, with cloud revenue accelerating to 31% and the company achieving its first full year of GAAP profitability. Analyst sentiment is overwhelmingly positive with 67% buy ratings and a $161.93 consensus target.
Outlook remains favorable with AI platform adoption and enterprise deal expansion driving growth, though valuation metrics appear stretched with EV/EBITDA at 184x. Key risks include competitive pressures in software and execution challenges in maintaining cloud momentum. The stock's proximity to 52-week highs suggests potential for consolidation near current levels.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Trailing returns across standard periods
Latest headlines on both assets
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →